(Celecoxib + famciclovir) is under clinical development by Virios Therapeutics and currently in Phase II for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase II drugs for Fibromyalgia (Fibromyalgia Syndrome) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Celecoxib + famciclovir)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Celecoxib + famciclovir) overview
IMC-1 a fixed dose combination of celecoxib and famciclovir is under development for the treatment of irritable bowel disease, chronic fatigue syndrome and fibromyalgia. The drug candidate is an oral medication that is designed to suppress the suspected tissue-resident herpes virus and to alleviate fibromyalgia symptoms. It acts by targeting DNA polymerase and Prostaglandin G/H Synthase 2.
Virios Therapeutics overview
Virios Therapeutics (Virios Therapeutics), formerly Innovative Med Concepts LLC is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray that is used to treat viral pharyngitis that provides relief to cancer patients undergoing head and neck radiation; and IMC-1, a novel proprietary fixed dose combination medication that is designed to treat chronic tissue-resident herpes simplex virus type 1. It also conducts research on various chronic ailments. The company collaborates with other organizations for their pipeline development, licensing and commercialization. Virios Therapeutics is headquartered in Tuscaloosa, Alabama, the US.
For a complete picture of (Celecoxib + famciclovir)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
